Salix Coronary Plaque vs vascuCAP

Direct competitors — feature-level head-to-head below. Comparability 85/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Salix Coronary Plaque

by Artrya Limited

vascuCAP

by Elucid Bioimaging

AI Verdict

Both Salix Coronary Plaque and vascuCAP are FDA-cleared AI tools designed for analyzing CT angiography scans to assess coronary artery plaque. While Salix focuses on near real-time, point-of-care diagnosis of coronary artery disease, including stenosis and high-risk plaque features, vascuCAP provides histologically-validated quantification of plaque composition and explicit risk stratification for stroke and heart attack to optimize treatment decisions. Therefore, the choice between them depends on the desired depth of plaque characterization and the primary clinical objective, whether it's rapid diagnosis or detailed risk assessment for treatment planning.

Choose Salix Coronary Plaque if…

Choose Salix Coronary Plaque if you require near real-time, point-of-care assessment of CCTA scans for rapid and accurate diagnosis of coronary artery disease. This tool is ideal for quickly identifying and quantifying coronary plaque and stenosis, including high-risk plaque features, to support immediate clinical decision-making.

View Salix Coronary Plaque →

Choose vascuCAP if…

Choose vascuCAP (ElucidVivo/PlaqueIQ) if your primary need is histologically-validated, in-depth quantification and characterization of plaque composition for comprehensive cardiovascular risk stratification. This tool excels in providing detailed insights into specific plaque components to optimize personalized treatment decisions and for scenarios requiring advanced plaque analysis beyond rapid diagnosis.

View vascuCAP →

When choosing between Salix Coronary Plaque and vascuCAP (now ElucidVivo/PlaqueIQ), physicians should consider their primary focus and workflow. Salix Coronary Plaque excels in providing near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans. Its strengths lie in rapid diagnosis, identifying high-risk plaque features like low-attenuation plaque and napkin-ring sign, and offering automated report generation. This tool is particularly well-suited for practices prioritizing immediate insights into coronary artery disease and streamlined CCTA analysis.

In contrast, vascuCAP offers a more in-depth, histologically-validated plaque quantification and characterization from CT angiograms. It provides detailed analysis of plaque composition, including lipid-rich necrotic core and intraplaque hemorrhage, and supports risk stratification for stroke and heart attack. The key practical difference lies in Salix’s emphasis on rapid, point-of-care coronary assessment versus vascuCAP’s comprehensive, histologically-validated plaque characterization for broader cardiovascular risk assessment. Physicians primarily focused on quick CCTA interpretation and coronary disease diagnosis may lean towards Salix Coronary Plaque. Those requiring detailed plaque composition analysis, 3D visualization, and comprehensive cardiovascular risk stratification for personalized treatment decisions, extending beyond just coronary arteries, would find vascuCAP more aligned with their needs.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Salix Coronary Plaque	vascuCAP
Pricing	Contact for pricing	Contact for pricing
Deployment	Cloud	Cloud and on-premise
FDA Status	Yes AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Salix Coronary Plaque

Tool A emphasizes a highly streamlined and efficient user experience with features like web-based access, near real-time, point-of-care assessment, and automated report generation. It also includes a personalized 3D heart model for improved communication. While Tool B offers 3D visualization and workflow integration, Tool A's focus on speed and immediate clinical utility gives it a slight edge in overall usability.

Clinical Value

vascuCAP

Tool B offers superior clinical value due to its 'histologically-validated' plaque quantification, providing a deeper and more precise characterization of vulnerable plaque components like lipid-rich necrotic core and intraplaque hemorrhage. This level of detail, validated against ground-truth histology, is crucial for advanced risk stratification and personalized treatment decisions for stroke and heart attack prevention.

Pricing & Value

Salix Coronary Plaque

Tool A provides greater transparency regarding its pricing model by explicitly mentioning a per-scan assessment and the associated US CPT reimbursement rate of US$950 per assessment. This offers a clearer understanding of the potential revenue and value proposition for healthcare providers compared to Tool B's 'contact for pricing' approach.

Enterprise Readiness

Salix Coronary Plaque

Tool A demonstrates stronger enterprise readiness by explicitly listing a broader range of compliance certifications, including HIPAA, GDPR, HITECH, SOC 2, and multiple ISO standards. Furthermore, it offers flexible deployment options including SaaS, on-premise, and hybrid models, catering to diverse IT infrastructures and regulatory environments.

Innovation

vascuCAP

Tool B exhibits a higher degree of innovation through its 'histologically-validated' plaque quantification, which provides 'CT Virtual Histologyu2122' by objectively quantifying plaque morphology against ground-truth histology. This offers a deeper, more scientifically advanced understanding of plaque vulnerability beyond morphological features, enabling more precise risk assessment and personalized treatment.

Support & Docs

Tie

Neither tool provides readily accessible public information regarding comprehensive support services or detailed documentation beyond general contact options or mentions of user guides. Without specific details on user manuals, FAQs, or dedicated support portals, it is not possible to distinguish between the two.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Salix Coronary Plaque	vascuCAP
Product Name	Salix Coronary Plaque	vascuCAP (now ElucidVivo/PlaqueIQ)
Company	Artrya Limited	Elucid Bioimaging
Description	FDA-cleared, AI-driven, web-based software that provides near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease.	FDA-cleared AI software for non-invasive CT angiography analysis, quantifying plaque composition and assessing cardiovascular risk to optimize treatment decisions.
Key Feature: Plaque Quantification	Detection and quantification of coronary plaque (atherosclerosis); Identification of high-risk plaque features (e.g., low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign); Quantification of calcifications (calcium scoring)	Histologically-validated plaque quantification and characterization; Quantification of lipid-rich necrotic core, calcification, non-calcified matrix, intraplaque hemorrhage
Key Feature: Risk Assessment	Near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease.	Risk stratification for stroke and heart attack; Support for personalized treatment decisions

Videos

Demos, reviews, and walkthroughs featuring Salix Coronary Plaque and vascuCAP.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the key differences in plaque characterization capabilities between Salix Coronary Plaque and vascuCAP?

Salix Coronary Plaque detects and quantifies coronary plaque, including high-risk features such as low-attenuation plaque, spotty calcification, positive remodeling, and the napkin-ring sign, along with stenosis assessment and calcium scoring. In contrast, vascuCAP provides histologically-validated plaque quantification and characterization, specifically quantifying lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage.

What kind of clinical validation supports the plaque analysis of each tool?

vascuCAP (now ElucidVivo/PlaqueIQ) explicitly states 'histologically-validated plaque quantification and characterization,' with its algorithms validated by expert pathologists using a biobank of tissue specimens. Salix Coronary Plaque is an FDA-cleared, AI-driven software that provides assessment of coronary artery plaque and stenosis from CCTA scans.

What are the differences in their approach to cardiovascular risk assessment?

Salix Coronary Plaque aids in the rapid and accurate diagnosis of coronary artery disease and identifies high-risk plaque features. vascuCAP focuses on assessing cardiovascular risk to optimize treatment decisions and provides risk stratification for stroke and heart attack.

Do both tools offer integration with existing hospital systems and workflows?

Salix Coronary Plaque features integrated workflow management and automated report generation. vascuCAP explicitly mentions DICOM integration and PACS/EMR interoperability.